Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intermittent Catheterisation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Intermittent Catheterisation. Displaying page 1 of 1.
    EudraCT Number: 2005-003068-47 Sponsor Protocol Number: UROBOTOX 1 Start Date*: 2005-09-22
    Sponsor Name:Region Skåne, Universitetssjukhuset i Lund, Urologiska kliniken
    Full Title: Behandling med botulinumtoxin vid neurogen blåsfunktionsstörning
    Medical condition: The trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002556-32 Sponsor Protocol Number: ANTIC:6672 Start Date*: 2013-09-05
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Antibiotic treatment for intermittent bladder catheterisation: A randomised controlled trial of once daily prophylaxis (The AnTIC study)
    Medical condition: Recurrent urinary tract infection in people who use intermittent bladder catheterisation.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10064736 Antibiotic prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004853-59 Sponsor Protocol Number: EX6018-4758 Start Date*: 2021-08-16
    Sponsor Name:Novo Nordisk A/S
    Full Title: ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
    Medical condition: Atherosclerotic cardiovascular disease Chronic kidney disease Systemic inflammation
    Disease: Version SOC Term Classification Code Term Level
    26.0 10047065 - Vascular disorders 10051615 Atherosclerotic cardiovascular disease LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.1 10022891 - Investigations 10067394 hs-CRP increased LLT
    21.0 10022891 - Investigations 10011418 CRP increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Ongoing) SK (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) GR (Ongoing) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) BG (Ongoing) PT (Trial now transitioned) IT (Ongoing) HU (Ongoing) CZ (Trial now transitioned) LV (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003244-13 Sponsor Protocol Number: D4280C00016 Start Date*: 2015-04-17
    Sponsor Name:Pfizer Inc.
    Full Title: A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children fr...
    Medical condition: Complicated urinary tract infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005053 10046577 Urinary tract infections HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) GR (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-003141-42 Sponsor Protocol Number: EX9924-4473 Start Date*: 2019-07-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) SK (Ongoing) DE (Ongoing) BE (Ongoing) AT (Ongoing) ES (Ongoing) CZ (Ongoing) HR (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003842-18 Sponsor Protocol Number: A301223 Start Date*: 2014-04-24
    Sponsor Name:Erasmus MC
    Full Title: Prevention of renal and bladder damage in children with spina bifida by means of early injections with Botulinum-Toxin-A (Botox): a pilot study.
    Medical condition: Neurogenic bladder function disease in spina bifida patients.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10030685 Open spina bifida LLT
    16.1 100000004850 10041531 Spina bifida without mention of hydrocephalus LLT
    16.1 100000004857 10029280 Neurogenic bladder, not otherwise specified LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-007053-13 Sponsor Protocol Number: STEG-CORP_111802 Start Date*: 2009-07-31
    Sponsor Name:Grachtenhaus-Apotheke, Inh. Klaus Stegemann e. K.
    Full Title: Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase III zur Bestimmung der Wirksamkeit, Verträglichkeit und Sicherheit von intravesikal verabreichter Oxybutynin-Lösung bei Kindern/J...
    Medical condition: bladder disorder (detrusor hyperactivity caused by neurogenic disorder)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061011 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004995-20 Sponsor Protocol Number: 05/SUR/3360E Start Date*: 2006-06-08
    Sponsor Name:R and D Department, Cardiff and the Vale NHS Trust
    Full Title: A Prospective, Single-Arm, Open-label Study to Investigate the Efficacy and Safety of Intravesical Injection of Botulinum Toxin Type-A (500 Units Dysport®) for the Management of Idiopathic Overacti...
    Medical condition: Idiopathic Overactive bladder syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029279 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004996-40 Sponsor Protocol Number: 04/SUR/3070 Start Date*: 2006-06-08
    Sponsor Name:R and D Department, Cardiff and the Vale NHS Trust
    Full Title: A Prospective, Single-Arm, Open-label Study to Investigate the Efficacy and Safety of Intravesical Injection of Botulinum Toxin Type-A (750 Units Dysport®) for the Management of Neurogenic Detrusor...
    Medical condition: Neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029279 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005844-47 Sponsor Protocol Number: D6580C00010 Start Date*: 2021-05-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants wit...
    Medical condition: Heart Failure with Left Ventricular Ejection Fraction > 40%
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) SK (Completed) CZ (Completed) DK (Completed) BG (Ongoing) HU (Completed) PL (Ongoing) NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005295-33 Sponsor Protocol Number: S54913 Start Date*: 2013-03-08
    Sponsor Name:UZ Leuven-Department of Urology
    Full Title: Monocentric, open-label, phase III study that compares the efficiency and tolerance between intravesical oxybutynin and oral fesoterodine in children (5-16y) with neurogenic detrusor overactivity.
    Medical condition: children with neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10041524 Spina bifida PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003048-52 Sponsor Protocol Number: 527.51 Start Date*: 2007-10-29
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bla...
    Medical condition: Neurogenic Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029279 Neurogenic bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA